Picard Medical, Inc. · AMEX:PMI
Picard Medical — IPO Roadshow (July 2025)
23 slides from Picard Medical's IPO roadshow presentation, Jul 18, 2025
Slide 1: Picard Medical Inc. Issuer Free Writing Prospectus
SynCardia's products are approved for sale in the U.S. and Canada only. © SynCardia Systems, LLC. All rights reserved | www. SynCardia .com Picard Medical Inc. Proposed NYSE American Ticker: PMI Filed pursuant to Rule 433 of the Securities Act of 1933, as amended. Issuer Free Writing Prospectus date
Slide 2: Forward-Looking Statements
This Presentation contains statements that are “forward - looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements include all statements that do not relate solely to historical or current facts and can generally be identified by t
Slide 3: Free Writing Prospectus Notice and Disclaimer
Neither the Company nor any of its subsidiaries, affiliates, representatives or advisors assumes any responsibility for or makes any representation or warranty (express or implied) as to, the reasonableness, completeness, accuracy or reliability of the estimates and information contained herein, whi
Slide 4: Our Mission
Our Mission To pioneer the future of heart replacement by providing the world’s first Total Artificial Heart and developing the next - generation system as an alternative to transplantation SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly own
Slide 5: SynCardia At-a-Glance
Market Leader: Global innovator in total artificial heart technology and a wholly owned subsidiary of Picard Medical, Inc. (Proposed NYSE American Ticker: PMI). Only FDA - Approved TAH: The SynCardia Total Artificial Heart (“STAH”) is the only commercially available total artificial heart approved b
Slide 6: The Initial Public Offering Summary
The Initial Public Offering Summary SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 6 Picard Medical, Inc. Issuer NYSE American Proposed Exchange PMI Prop
Slide 7: Use of Proceeds
Use of Proceeds 1 SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 7 Purpose Amount Category • R&D for our fully implantable system including early feasibi
Slide 8: Driving Scalable Growth with an Experienced, Results-Focused Team
Driving Scalable Growth with an Experienced, Results - Focused Team SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 8 CEO Patrick NJ Schnegelsberg COO Mat
Slide 9: Years of Leadership: From First FDA Approval to Future Innovation
20 Years of Leadership: From First FDA Approval to Future Innovation - Proven Legacy in Total Artificial Hearts SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights rese
Slide 10: SynCardia is Built to Scale: Here's Why
SynCardia is Built to Scale: Here's Why SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 10 Leader in High - Demand Market We believe SynCardia is the lead
Slide 11: The Problem: Shortage of Donor Hearts Leaves Thousands Waiting
The Problem: Shortage of Donor Hearts Leaves Thousands Waiting SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 11 Demand for Donor Hearts Exceeds Supply 1
Slide 12: The Solution: The First FDA Approved Total Artificial Heart
The Solution: The First FDA Approved Total Artificial Heart — Designed for Hospital and Home Use SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 12 Each p
Slide 13: Clinically Validated: Peer-Reviewed Outcomes Demonstrate STAH Survival Advantage
Survival Rate to transplantation (vs. 46% in control group) 1 79% Survival Rate at one year (vs. 31% in control group) 1 70% 75% Survival Rate at one year after heart transplant 2 Over 2,100 SynCardia Total Artificial Heart Implants 3 Over 7.5 Years Longest Living patient on the STAH 3 Clinically Va
Slide 14: Utilized by High Volume Transplant Centers Across the U.S. and Europe
Utilized by High Volume Transplant Centers Across the U.S. and Europe SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 14 Centers of Excellence 1 High Volu
Slide 15: Lev'Veon's Story: Courage, Innovation, and a Lifesaving First
Lev’Veon’s Story: Courage, Innovation, and a Lifesaving First SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 15 Age: 10 years old Diagnosis: Myocarditis
Slide 16: From Implant to Advocacy: Empowering Lives with the STAH
From Implant to Advocacy: Empowering Lives with the STAH SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 16 Johnny is now the co - founder and CEO of Uniq
Slide 17: Near-Term Growth Drivers: Site Expansion, Education, Access and Reimbursement
Near - Term Growth Drivers: Site Expansion, Education, Enhancing Access and Reimbursement SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 17 Protect exist
Slide 18: Mid-Term Growth Drivers: Label Expansion and Approvals
Mid - Term Growth Drivers: Label Expansion and Approvals Set to Fuel U.S. and Global Commercial Momentum SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 1
Slide 19: Long-Term Market Growth: Driven by R&D Pipeline and IP-Backed Innovation
Long - Term Market Growth: Driven by R&D Pipeline and IP - Backed Innovation SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 19 2H28 1H28 2H27 1H27 2H26 1
Slide 20: Decades of Clinical Leadership in BTT Patients
Decades of Clinical Leadership in BTT Patients: SynCardia’s Total Artificial Heart Outpaces Emerging Competitors SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights res
Slide 21: STAH Growth Trajectory: Regional Mix and Sales 2022–2024
STAH Growth Trajectory: Regional Mix and Sales 2022 – 2024 SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 21 $0 $1 $2 $3 $4 $5 - 5 10 15 20 25 30 2022 20
Slide 22: Investment Drivers: Validated, Protected and Positioned for Growth
Investment Drivers: Validated, Protected and Positioned for Growth SynCardia's products are approved for sale in the U.S. and Canada only. SynCarida Systems, LLC is a wholly owned subsidiary of Picard Medical Inc. © SynCardia Systems, LLC. All rights reserved. 22 Leader in High - Demand Market Captu
Slide 23: Addresses Most Severe Patients; Medical Advice Disclaimer
Addresses Most Severe Patients Delivering Proven Outcomes in the Toughest Cases SynCardia Systems, LLC – a Picard Medical Company The STAH is approved for sale in the US and in Canada where it is indicated for use in cardiac transplant - eligible patients at risk of imminent death from biventricular